According to Reuters, the WHO is also leading a trial into whether remdesivir, Gilead’s antiviral treatment, can be used for Covid-19 infections.
The US Food and Drug Administration withdrew its emergency use authorization for the drug earlier this month and trials around the world, including trials sponsored by the World Health Organization and the National Institutes of Health, were halted.
„Based on the analysis and on the review of the published evidence, the executive group of the Solidarity / recovery trial has … after the deliberation … concluded that hydroxychloroquine arm will be stopped from the Solidarity Trial,“ Ana Maria Henao Restrepo, Medical Officer, Department of Immunization Vaccines and Biologicals at WHO said on Wednesday at a press conference in Geneva.
There were more deaths among those patients who were given the drug, hydroxychloroquine, than patients who received standard care, researchers found.
Dass Raoults Forschungsergebnisse auf eine solche negative Resonanz bei der Obrigkeit und den Mainstream-Medien trafen, lässt sich dadurch erklären, dass das Aufkommen eines effizienten und billigen Medikamentes auf dem französischen und europäischen Markt die Projekte von zwei Pharmafirmen, Gilead und Abbvie, durchkreuzen würde. Diese beiden Firmen stellen zwei ebenfalls gegen Covid-19 eingesetzte Medikamente her: Gilead stellt das sehr teure Anti-Ebola-Mittel Remdesivir her und Abbvie Kaletra ein Kombinationspräparat aus den Anti-HIV-Medikamenten Lopinavir und Ritonavir. Bekanntlich reicht der Arm der starken Pharmaindustrie bis in die hohen Sphären der französischen Gesundheitspolitik. Und aus diesen hohen Sphären haben die oben erwähnten Firmen drei Personen, die sich – was für eine Überraschung! – als prominenteste Gegner Raoults und des Hydroxychloroquins geoutet haben:
The U.S. Centers for Disease Control and Prevention has removed from its website highly unusual guidance informing doctors on how to prescribe hydroxychloroquine and chloroquine, drugs recommended by President Donald Trump to treat the coronavirus.
A blockchain investor named James Todaro tweeted that an 85-year-old malaria drug called chloroquine was a potential treatment and preventative against the disease caused by the new coronavirus. Todaro linked to a Google doc he’d cowritten, explaining the idea.
“There has been anecdotal evidence that it is promising; that’s why we’re going ahead,” he added, noting that some patients have a pre-existing condition or medication regimen that prevents them from taking it.
An increase in the supply from the federal government, Cuomo added, would allow New York to lift the 14-day restriction.
Peter Navarro, the top trade and manufacturing aide to the president who is coordinating the use of the Defense Production Act for the White House, told CNN’s John Berman Monday that he believes a „second opinion“ is needed about hydroxychloroquine as a treatment.
„I let (Fauci) speak for himself, John, but I would have two words for you: second opinion,“ Navarro said. „Doctors disagree about things all the time.“
Trump has been repeatedly contradicted by public health experts including his own top infectious diseases adviser, Dr Anthony Fauci, who has warned that there is only “anecdotal evidence” that the drugs could be helpful.
The Department of Health and Human Services said Sunday hydroxychloroquine and chloroquine products can be distributed and prescribed by doctors through the Strategic National Stockpile “to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible.”
HHS said Germany’s Sandoz has already given 30 million doses of hydroxychloroquine to the Strategic National Stockpile, the federal government’s inventory of medical supplies for public health emergencies, while Bayer has donated a million doses of chloroquine.
President Trump said on Saturday that the federal government was placing millions of doses of a malaria drug in the federal stockpile of emergency medical supplies to make it available for coronavirus patients, even though the drug has not been approved for Covid-19 treatment and his top coronavirus advisers have warned that more study is needed to determine its safety and efficacy.
Though advisers, including Dr. Anthony Fauci, have cautioned many times that more data is needed on the drug, hydroxychloroquine, Mr. Trump, in a White House briefing, went so far as to urge patients to take it.